ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressPRNewsWire • 09/13/24
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024PRNewsWire • 08/05/24
ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate CancerSeeking Alpha • 05/29/24
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024PRNewsWire • 05/14/24
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferencePRNewsWire • 04/09/24
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023PRNewsWire • 02/13/24
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePRNewsWire • 02/06/24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumPRNewsWire • 01/25/24
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023PRNewsWire • 12/12/23
ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerPRNewsWire • 09/18/23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023PRNewsWire • 08/08/23
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023PRNewsWire • 05/09/23
ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate CancerPRNewsWire • 04/12/23